GW-433908

Known as: GW 433908, GW433908 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2013
024620012013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
GW433908 is the water-soluble, phosphate ester prodrug of the human immunodeficiency virus type 1 protease inhibitor amprenavir… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2004
2004
OBJECTIVE To compare the efficacy, durability, and tolerability of GW433908 (908), 1400 mg twice-daily (BID), with nelfinavir… (More)
Is this relevant?
2004
2004
OBJECTIVES To investigate the emergence of resistance to GW433908 (908), a protease inhibitor (PI) with demonstrated antiviral… (More)
Is this relevant?
2004
2004
OBJECTIVE To evaluate the safety and pharmacokinetic interaction between GW433908, ritonavir (RTV), and efavirenz (EFV… (More)
Is this relevant?
2004
2004
This study compared the plasma amprenavir pharmacokinetics of the human immunodeficiency virus (HIV) protease inhibitors… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2004
Review
2004
Fosamprenavir (GW433908, Lexiva, Telzir) is an oral prodrug of the protease inhibitor (PI) amprenavir, with a reduced daily pill… (More)
Is this relevant?
2002
2002
These two Phase I, open-label, single-dose, randomized, crossoverstudies in 40 healthymale subjects investigated the… (More)
Is this relevant?
2002
2002
We compared seminal plasma pharmacokinetic data for the investigational amprenavir prodrug GW433908 with those for amprenavir and… (More)
Is this relevant?
Review
2002
Review
2002
Protease inhibitors block the protease enzyme of HIV-1. When new viral particles break off from an infected cell, protease cuts… (More)
Is this relevant?
Review
2001
Review
2001
 
Is this relevant?